Leukopenia

Leukopenia — scientific infographic poster

Table of Contents

  1. What Leukopenia Is
  2. Types of Leukopenia
  3. Causes and Risk Factors
  4. Symptoms
  5. Diagnosis and Lab Tests
  6. Conventional Treatment
  7. Nutritional and Natural Approaches
  8. Complications
  9. Prognosis
  10. Prevention
  11. Key Research Papers
  12. Connections
  13. Featured Videos

What Leukopenia Is

Leukopenia is defined as a white blood cell (WBC) count below 4,000 cells per microliter (4.0 × 109/L) in adults. White blood cells are the cellular soldiers of your immune system, and when their numbers drop too low, your body loses a critical layer of defense against infections, bacteria, viruses, and fungi.

Your blood contains several distinct types of white blood cells, each with a specialized role:

Leukopenia can reflect a reduction in any or all of these cell types. The most clinically dangerous form is neutropenia — a specific drop in the absolute neutrophil count (ANC) below 1,500 cells/mcL — because neutrophils provide the first and fastest defense against life-threatening bacterial infections. When someone with leukopenia develops a fever, it is a medical emergency until proven otherwise.

It is important to distinguish leukopenia (broad WBC reduction) from conditions that selectively reduce just one cell line. The overall WBC count may be only mildly reduced while a specific, critically important subset — particularly neutrophils — is severely depleted.

Back to Table of Contents

Types of Leukopenia

Leukopenia is an umbrella term. The specific type is identified by which white blood cell line is reduced, which in turn points toward different causes and carries different risks.

Neutropenia

The most clinically significant form. Defined as an absolute neutrophil count (ANC) below 1,500 cells/mcL. Severity is graded as follows:

ANC is calculated from the complete blood count (CBC) differential: ANC = WBC × (% neutrophils + % bands) ÷ 100.

Lymphocytopenia

Defined as a lymphocyte count below 1,000 cells/mcL in adults (below 3,000 cells/mcL in children under 2 years). Lymphocytopenia impairs antibody production and cell-mediated immunity, creating vulnerability to viral infections and opportunistic organisms such as Pneumocystis jirovecii. Human immunodeficiency virus (HIV) infection is a major cause of progressive CD4+ T-lymphocytopenia.

Monocytopenia

Rare; a monocyte count below 200 cells/mcL. Associated with hairy cell leukemia, aplastic anemia, and some immunodeficiency states. Monocytopenia reduces the ability to clear fungal infections and mount chronic inflammatory responses.

Eosinopenia

An eosinophil count below 100 cells/mcL. Most commonly seen during acute bacterial infections, Cushing syndrome, or steroid treatment — where cortisol drives eosinophils out of circulation into tissues. Generally not itself clinically problematic.

Pan-leukopenia

A reduction in all white blood cell types simultaneously. This pattern suggests global bone marrow failure, as seen in aplastic anemia, myelodysplastic syndrome (MDS), or following aggressive chemotherapy or radiation. Pan-leukopenia is often accompanied by anemia and thrombocytopenia (low platelets), a combination called pancytopenia.

Benign Ethnic Neutropenia (Duffy-Null Associated Neutrophil Count)

An important variant that affects a significant proportion of people of African, Afro-Caribbean, and some Middle Eastern descent. These individuals have baseline ANC values that run lower than standard ranges as a normal constitutional variant — not due to disease — and do not have increased susceptibility to infection. Only part of the group falls under 1,500 cells/mcL: a 2026 study of 8,018 healthy Duffy-null adults set reference intervals of 1,210–5,390 in the United States, 1,185–5,462 in the United Kingdom, 1,140–5,290 in Saudi Arabia and 820–6,370 in Namibia (PMID 41191521). Misdiagnosis as pathologic neutropenia leads to unnecessary workup and, in some cases, disqualification from otherwise appropriate medications. It is identified by a gene test: a homozygous variant in the ACKR1 gene, called the Duffy-null genotype (PMID 42125771). In the 2026 study there was no significant ANC difference between Black and non-Black Duffy-null participants, and hospital ranges labelled 21.7% (United States) to 50.9% (Saudi Arabia) of these healthy people as neutropenic (PMID 41191521).

The clozapine label sets a separate starting limit for this group: at least two baseline counts, and clozapine not started below 1,000/µL rather than 1,500/µL. A 2026 UK guideline describes offering the gene test to all people starting clozapine, and states that the naturally low counts carry no increased infection risk (PMID 42125771).

Back to Table of Contents

Causes and Risk Factors

Leukopenia arises from three fundamental mechanisms: reduced production of WBCs in the bone marrow, accelerated destruction of WBCs in circulation, or abnormal distribution (sequestration) of WBCs out of the bloodstream. Often more than one mechanism operates simultaneously.

Bone Marrow Suppression

When the factory that makes blood cells is damaged or overwhelmed, all cell lines suffer:

Medications

Drug-induced leukopenia is common and often overlooked. Key offenders include:

Autoimmune and Inflammatory Conditions

Infections

Many infections temporarily suppress WBC production or accelerate WBC destruction:

Nutritional Deficiencies

Underappreciated but correctable causes:

Hypersplenism

An enlarged spleen (from portal hypertension due to cirrhosis, lymphoma, storage diseases such as Gaucher disease, or chronic infection) acts as a WBC sink — sequestering and destroying circulating cells faster than the marrow can replace them. The spleen normally holds about one-third of the platelet pool; in hypersplenism, it traps an abnormally large fraction of all blood cell types.

Congenital and Inherited Causes

Back to Table of Contents

Symptoms

Leukopenia is frequently asymptomatic when mild — many people discover a low WBC count incidentally on a routine complete blood count ordered for an unrelated reason. The body's reserves of mature neutrophils (both in marrow and marginated along vessel walls) provide a buffer before clinical consequences appear.

As the WBC count — and especially the ANC — falls further, the immune system's first-response capacity erodes, and characteristic problems emerge:

Recurrent and Prolonged Infections

This is the hallmark consequence. Infections that would be minor in a healthy person become prolonged, severe, or recurrent. Common patterns include:

Mouth Sores

Aphthous ulcers (painful open sores on the gums, tongue, and inner cheeks) are characteristic of neutropenia, particularly in cyclic neutropenia where they appear predictably during each nadir. The mouth's bacterial burden is normally kept in check by salivary neutrophils; when those disappear, minor mucosal breaks become persistent ulcers.

Fever

In a person with an ANC below 500 cells/mcL, a temperature above 38.3°C (101°F) — or 38.0°C sustained over one hour — is a medical emergency called febrile neutropenia. The fever may be the only sign of a potentially life-threatening infection because the usual inflammatory response (pus, localized pain, swelling) is blunted without adequate neutrophils. Emergency departments treat this as urgent from arrival.

Fatigue and Malaise

Non-specific but common, particularly when leukopenia accompanies anemia (as in pancytopenia from aplastic anemia or MDS). Chronic low-grade infections also contribute to persistent fatigue.

Delayed Wound Healing

Neutrophils are essential for clearing bacteria from wounds in the first 24–48 hours. Without adequate neutrophil activity, even minor cuts and surgical incisions heal slowly and are prone to secondary infection.

Opportunistic Infections with Lymphocytopenia

When lymphocytes are specifically depleted (as in advanced human immunodeficiency virus or after organ transplant), the immune defects are different and in some ways more insidious — the body loses protection against organisms that a normal immune system holds in check indefinitely:

Back to Table of Contents

Diagnosis and Lab Tests

The diagnosis of leukopenia is straightforward — a single complete blood count with differential establishes it. The real diagnostic work is identifying why the WBC count is low, which requires systematic investigation.

Complete Blood Count (CBC) with Differential

The foundation of diagnosis. A complete blood count reports the total WBC count and the differential (percentage and absolute number of each WBC type). Key values to extract:

Serial CBCs over 4–8 weeks can reveal a cyclic pattern, which is diagnostic of cyclic neutropenia.

Peripheral Blood Smear

A trained hematologist examines the size, shape, and structure of blood cells under the microscope. Critical findings include:

Nutritional Testing

Infectious Disease Testing

Autoimmune Testing

Medication Review

A detailed timeline of all prescription medications, over-the-counter drugs, and supplements compared against the timing of the WBC drop is one of the most important diagnostic steps. Drug-induced leukopenia typically appears within days to weeks of starting the offending agent.

Bone Marrow Biopsy and Aspiration

Indicated when the cause remains unclear, when malignancy is suspected, or when the count is severely low. Allows assessment of marrow cellularity, maturation arrest (neutrophils produced but not released), fibrosis, infiltration by malignant cells, and cytogenetics (chromosomal abnormalities pointing to MDS or leukemia). Copper deficiency causes marrow changes that closely mimic MDS — vacuolation of precursors — making copper measurement essential before a marrow biopsy is interpreted.

Back to Table of Contents

Conventional Treatment

Treatment targets the underlying cause of leukopenia. There is no single universal therapy — a correct diagnosis drives the intervention.

Treatment of the Underlying Cause

Granulocyte-Colony Stimulating Factor (G-CSF)

G-CSF (filgrastim, pegfilgrastim, biosimilars) is a protein that stimulates the bone marrow to produce and release neutrophils rapidly. It is the cornerstone pharmacological treatment for:

Febrile Neutropenia: A Medical Emergency

Any patient with ANC <500 cells/mcL who develops fever (T >38.3°C or >38.0°C sustained over one hour) is treated in hospital as an emergency. Standard management:

A 2014 Cochrane review of 14 randomized trials (1,553 people) tested adding a colony-stimulating factor such as G-CSF to antibiotics. Overall mortality was not improved (hazard ratio 0.74, 95% confidence interval 0.47 to 1.16; low quality evidence), but neutropenia was shorter, fever recovery faster and antibiotic use shorter, and fewer people stayed in hospital over 10 days (risk ratio 0.65) (PMID 25356786).

Risk stratification using the Multinational Association for Supportive Care in Cancer score identifies low-risk patients who may be candidates for oral antibiotics and outpatient management, an approach mainly used at centers experienced in it.

Antimicrobial Prophylaxis for Prolonged Neutropenia

Patients expected to have ANC <100 cells/mcL for more than 7 days (e.g., after induction chemotherapy for acute leukemia) benefit from:

Clozapine Blood-Count Monitoring

The prescribing information describes absolute neutrophil count (ANC) monitoring weekly for the first 6 months, every 2 weeks for the next 6 months, then monthly. Clozapine is withheld if the ANC falls below 1,000/µL and discontinued if it falls below 500/µL. Until 24 February 2025 the US required prescribers, pharmacies and patients to enrol in a monitoring programme (REMS); the FDA ended that requirement but still recommends monitoring as the prescribing information describes.

Back to Table of Contents

Nutritional and Natural Approaches

Natural approaches to leukopenia are most effective when a specific deficiency or modifiable factor underlies the low WBC count. They are complementary to — not replacements for — conventional treatment in serious cases.

Correcting Nutritional Deficiencies

This is the highest-yield natural intervention:

Zinc

Zinc is required for neutrophil maturation and function. Mild zinc deficiency impairs the oxidative burst that neutrophils use to kill bacteria. Dietary sources include red meat, shellfish (especially oysters), legumes, and nuts. Supplementation at Recommended Dietary Allowance (RDA) levels (8–11 mg/day) supports immune function. The US adult upper limit is 40 mg/day; as noted under Copper above, long-term intake above that level competes with copper absorption.

Vitamin D

Vitamin D receptors are expressed on nearly all immune cells including neutrophils, monocytes, and lymphocytes. Deficiency (serum 25-OH vitamin D <20 ng/mL) is associated with impaired immune cell differentiation and function. Correcting deficiency with vitamin D3 (1,000–4,000 international units (IU) daily, depending on baseline level) supports overall immune competence, though evidence for a direct WBC-raising effect is limited.

Astragalus (Huang Qi)

Astragalus membranaceus root has been used in Traditional Chinese Medicine for centuries as an immune tonic. Preclinical studies suggest polysaccharide components (Astragalus polysaccharides, APS) may stimulate hematopoiesis and WBC production in animal models, and some small Chinese clinical trials have explored its use alongside chemotherapy to reduce neutropenia duration. However, evidence from large, rigorous randomized controlled trials in humans is limited. Some integrative oncology centers incorporate astragalus into supportive care protocols, and herb-drug interactions and quality control of supplements are real concerns.

Beta-Glucans from Medicinal Mushrooms

Beta-1,3/1,6-glucans derived from Shiitake (Lentinula edodes), Maitake (Grifola frondosa), and Reishi (Ganoderma lucidum) are biological response modifiers that activate macrophages and natural killer cells via Dectin-1 receptors. Some clinical studies suggest that orally administered beta-glucans may modulate immune function and potentially reduce chemotherapy-induced immunosuppression, though they do not replace G-CSF for established febrile neutropenia risk management.

Echinacea

Echinacea preparations are widely used for short-term immune support. Evidence for their use specifically in leukopenia is minimal, and they are not established as a primary treatment. Echinacea is typically taken short-term (up to 10 days) in mild illness prevention but is not established as a treatment for established leukopenia.

Alcohol Reduction

Alcohol is directly toxic to bone marrow and suppresses neutrophil production. Chronic heavy alcohol use also causes folate deficiency. Reduction or elimination of alcohol intake can meaningfully improve WBC counts in people whose leukopenia is alcohol-related.

Infection Prevention Practices During Low-Count Periods

While not a "treatment" in the pharmacological sense, infection prevention is arguably the most important practical intervention for someone with leukopenia:

Back to Table of Contents

Complications

The severity of complications from leukopenia is directly proportional to the depth and duration of the WBC reduction, and the underlying cause.

Febrile Neutropenia

The most immediately life-threatening complication. In patients receiving chemotherapy, febrile neutropenia carries an overall mortality of 5–10% in the general population, rising to 20–30% in patients with septic shock or organ failure. Every hour's delay in antibiotic administration increases mortality: in a prospective cohort of 307 episodes, each hour raised the 28-day risk of death by 18% (hazard ratio 1.18), with 3.0% mortality when antibiotics came within 30 minutes against 18.1% at 31–60 minutes (PMID 24752269). This is why febrile neutropenia protocols in oncology centers are treated with the same urgency as a heart attack (ST-elevation myocardial infarction) protocol in cardiology.

Bacteremia and Sepsis

Organisms that the body normally clears within hours can establish bloodstream infections when neutrophils are absent. Gram-negative rods (Pseudomonas aeruginosa, Escherichia coli, Klebsiella species) are particularly dangerous. Their lipopolysaccharide outer membranes trigger massive cytokine release (septic shock), which can cause multi-organ failure within hours. Gram-positive organisms (Staphylococci, Streptococci, viridans streptococci from the mouth) are also common, particularly in patients with central venous catheters or mucositis.

Invasive Fungal Infections

Fungal infections are a particular danger during prolonged, profound neutropenia (>7 days, ANC <100). Invasive aspergillosis from inhaled mold spores can cause necrotizing pulmonary infection. Invasive candidiasis, particularly with fluconazole-resistant Candida glabrata or Candida krusei, is a major cause of mortality in neutropenic patients post-hematopoietic stem cell transplant.

Opportunistic Viral and Parasitic Infections

In lymphopenic states (human immunodeficiency virus, organ transplantation, high-dose corticosteroids):

Transformation to More Severe Hematologic Disease

In patients with myelodysplastic syndrome presenting as leukopenia, there is a 10–40% lifetime risk of progression to acute myeloid leukemia (AML), depending on the MDS subtype and cytogenetic risk category. Regular hematology follow-up with surveillance bone marrow biopsies is essential.

Chronic Organ Damage from Recurrent Infections

In patients with congenital neutropenia on long-term G-CSF, chronic mouth infections and gingivitis are nearly universal and can progress to significant periodontal bone loss. Recurrent lung infections can cause bronchiectasis over years.

Back to Table of Contents

Prognosis

The prognosis of leukopenia depends entirely on its cause, depth, and duration. This is one of those conditions where the underlying diagnosis matters far more than the WBC number itself.

Drug-Induced Leukopenia

Generally excellent if recognized promptly. Stopping the offending medication typically leads to WBC recovery within days to 3 weeks. Agranulocytosis from clozapine, once managed with G-CSF support through the nadir, usually resolves fully. The current clozapine label states that people who had severe neutropenia generally are not rechallenged, but that for some patients the risk of schizophrenia worsening from not restarting may be greater than the risk of neutropenia returning. A 2023 systematic review of 59 published cases reported successful rechallenge or continuation with colony-stimulating factors in 76% over an average of 1.9 years, limited by the small number of cases (PMID 36794520).

Nutritional Deficiency Leukopenia

Excellent with correction of the deficiency. B12-related neutropenia typically normalizes within 4–8 weeks of replacement therapy. Copper deficiency responds within weeks to months. These are among the most rewarding leukopenia diagnoses to make because they are fully correctable.

Chemotherapy-Induced Neutropenia

Predictable and manageable with appropriate G-CSF support and antibiotic prophylaxis. Modern supportive care has dramatically reduced mortality from febrile neutropenia and allowed more intensive chemotherapy regimens to be given safely.

Autoimmune Leukopenia

Variable. Primary autoimmune neutropenia in infants typically resolves spontaneously by age 2–4. Lupus-associated leukopenia often fluctuates with disease activity and improves with disease control. Felty syndrome can be refractory.

Aplastic Anemia-Associated Leukopenia

Depends on severity and treatment response. Severe aplastic anemia without treatment carries a high mortality; with hematopoietic stem cell transplantation (curative for eligible patients) or immunosuppression (antithymocyte globulin + cyclosporine), survival rates exceed 80–90% at specialized centers.

MDS-Associated Leukopenia

Prognosis stratified by the International Prognostic Scoring System (IPSS-R), incorporating cytogenetics, blast percentage, and cytopenias. Low-risk MDS may remain stable for years; high-risk MDS has median survival of 1–2 years without allogeneic stem cell transplantation.

Congenital Neutropenia

Lifelong condition requiring ongoing management. With modern G-CSF therapy, patients with severe congenital neutropenia lead relatively normal lives, though long-term G-CSF use carries a real risk of MDS/AML. In an international registry of 374 patients on long-term G-CSF, the cumulative incidence after 10 years was 21% for MDS/AML and 8% for death from sepsis; the MDS/AML figure was 40% in patients who responded less well to G-CSF and 11% in those who responded better (PMID 16497969). Later follow-up found that the yearly risk of MDS/AML levelled off at 2.3% after 10 years (PMID 20456363).

Back to Table of Contents

Prevention

Prevention strategies for leukopenia depend on the clinical context — what is preventable in one setting may not be relevant in another.

Monitoring During Myelosuppressive Therapy

Routine complete blood count monitoring is standard of care for any patient receiving chemotherapy, radiation therapy, or medications known to suppress bone marrow. Knowing when the nadir is expected (typically 7–14 days after cytotoxic chemotherapy) allows preemptive G-CSF administration and early detection of dangerous nadirs before febrile complications develop.

Primary G-CSF Prophylaxis

For chemotherapy regimens where the febrile neutropenia risk exceeds 20%, or in patients with risk factors (age >65, prior febrile neutropenia, poor nutritional status, comorbidities), pegfilgrastim given 24–72 hours after each chemotherapy cycle is standard preventive practice. This approach reduces hospitalization rates and allows treatment intensity to be maintained.

Trilaciclib is a newer intravenous drug given before chemotherapy to protect marrow cells. In pooled results of 3 placebo-controlled studies (242 people with extensive-stage small cell lung cancer), it lowered most measures of chemotherapy-induced low blood counts, with similar cancer outcomes (PMID 33895103). The FDA label dates first approval to 2021 and limits it to this cancer, with platinum/etoposide or topotecan regimens.

Monitoring for High-Risk Medications

Clozapine is the best-known example — regular ANC monitoring every month (and more frequently initially) has dramatically reduced clozapine-related agranulocytosis deaths compared to the pre-monitoring era. On February 24, 2025 the FDA stated that it no longer expects prescribers, pharmacies and patients to take part in the clozapine monitoring programme (REMS) or to report results before dispensing; it still recommends monitoring at the frequencies in the prescribing information. Similar monitoring is described for other drugs with known bone marrow risks (carbamazepine, propylthiouracil).

Nutritional Adequacy

Ensuring adequate intake of B12 (particularly in older adults, strict vegans, and those on metformin or proton pump inhibitors long-term), folate (especially in people who drink alcohol regularly or have malabsorption), and copper (especially after bariatric surgery) prevents the nutritional causes of leukopenia. Routine post-bariatric surgery micronutrient panels commonly include copper and ceruloplasmin.

Infection Prevention During Neutropenic Periods

Hand hygiene, dietary precautions (avoiding high-risk foods during severe neutropenia), prophylactic antibiotics and antifungals per protocol, and patient education about fever recognition and emergency response all contribute to preventing the complications of leukopenia even when the leukopenia itself cannot be prevented.

Vaccination When Counts Allow

Annual influenza vaccination and pneumococcal vaccination (PCV15/20 or PPSV23 as appropriate) are particularly important for immunocompromised patients. Timing matters — vaccines are given during periods of relative immune recovery, not during the nadir. Live vaccines (MMR, varicella, live attenuated influenza) are contraindicated in patients with significant leukopenia or on immunosuppressive therapy.

Back to Table of Contents

Key Research Papers

  1. Crawford J, et al. Myeloid growth factors. J Natl Compr Canc Netw. 2013;11(10):1266–1290. — PubMed PMID: 24142827 · doi:10.6004/jnccn.2013.0148
  2. Farruggia P, Dufour C. Diagnosis and management of primary autoimmune neutropenia in children: insights for clinicians. Ther Adv Hematol. 2015;6(1):15–24. — PubMed PMID: 25642312 · doi:10.1177/2040620714556642
  3. Hsieh MM, et al. Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med. 2007;146(7):486–492. — PubMed PMID: 17404350 · doi:10.7326/0003-4819-146-7-200704030-00004
  4. Palmblad J, Nilsson CC, Höglund P, Papadaki HA. How we diagnose and treat neutropenia in adults. Expert Rev Hematol. 2016;9(5):479–487. — PubMed PMID: 26778239 · doi:10.1586/17474086.2016.1142867
  5. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91(19):1616–1634. — PubMed PMID: 10511589 · doi:10.1093/jnci/91.19.1616
  6. Dale DC, Bolyard AA. An update on the diagnosis and treatment of chronic idiopathic neutropenia. Curr Opin Hematol. 2017;24(1):46–53. — PubMed PMID: 27841775 · doi:10.1097/MOH.0000000000000305
  7. Myles N, Myles H, Xia S, et al. Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand. 2018;138(2):101–109. — PubMed PMID: 29786829
  8. Corbeil O, Béchard L, Fournier É, et al. Clozapine rechallenge or continuation despite neutropenia or agranulocytosis using colony-stimulating factor: A systematic review. J Psychopharmacol. 2023;37(4):370–377. — PubMed PMID: 36794520
  9. Rosenberg PS, Alter BP, Bolyard AA, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood. 2006;107(12):4628–4635. — PubMed PMID: 16497969
  10. Rosenberg PS, Zeidler C, Bolyard AA, et al. Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. Br J Haematol. 2010;150(2):196–199. — PubMed PMID: 20456363
  11. Hibbs SP, Chipare I, Halawani AJ, et al. Multinational assessment of absolute neutrophil counts and white blood cell counts among healthy Duffy-null adults. Blood. 2026;147(3):290–298. — PubMed PMID: 41191521
  12. Murtough S, Stellakis O, Mills D, et al. ACKR1/Duffy-null genotype testing for clozapine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx). Br J Clin Pharmacol. 2026;92(7):1977–1990. — PubMed PMID: 42125771
  13. Badolato R, Alsina L, Azar A, et al. A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome. Blood. 2024;144(1):35–45. — PubMed PMID: 38643510
  14. Weiss J, Goldschmidt J, Andric Z, et al. Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies. Clin Lung Cancer. 2021;22(5):449–460. — PubMed PMID: 33895103
  15. Mhaskar R, Clark OA, Lyman G, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev. 2014;2014(10):CD003039. — PubMed PMID: 25356786
  16. Stella F, Marasco V, Levati GV, et al. Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial. Blood Adv. 2023;7(19):5996–6004. — PubMed PMID: 37450382
  17. Jamal F, Kouli A, Alsulaiman A, et al. Neutropenic Diet Versus Liberalized Diet in Patients With Cancer: A Systematic Review and Meta-Analysis. JCO Oncol Pract. 2026;OP2600405. — PubMed PMID: 42721418
  18. Rosa RG, Goldani LZ. Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia. Antimicrob Agents Chemother. 2014;58(7):3799–3803. — PubMed PMID: 24752269
  19. Shea B, Swinden MV, Tanjong Ghogomu E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013;2013(5):CD000951. — PubMed PMID: 23728635

PubMed topic searches:

  1. PubMed: Leukopenia causes and treatment
  2. PubMed: Neutropenia management
  3. PubMed: Febrile neutropenia
  4. PubMed: G-CSF neutropenia

Back to Table of Contents

Connections

Back to Table of Contents